IDEAYA Biosciences, Inc. Increase (Decrease) in Accounts Receivable
IDEAYA Biosciences, Inc. (IDYA) reported Increase (Decrease) in Accounts Receivable of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-02-17
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-12-31 was -$2.00K.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $19.00K, a 99.71% decline year-over-year.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was -$14.00K.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was -$3.00K, a 101.17% decline year-over-year.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2025 was $0.00.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2024 was $0.00.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$193.00K.
- IDEAYA Biosciences, Inc. increase (decrease) in accounts receivable for fiscal 2022 was -$892.00K.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month | Increase (Decrease) in Accounts Receivable 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-17 | ||||
| 2024-12-31 | -$2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $17.00K derived: sum of 2 quarters · filed 2026-02-17 | $3.00K derived: sum of 3 quarters · filed 2026-02-17 | $0.00 10-K · filed 2026-02-17 | -$15.00K 10-K · filed 2025-02-18 |
| 2024-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $5.00K derived: sum of 2 quarters · filed 2024-11-04 | $2.00K 10-Q · filed 2024-11-04 | -$6.68M derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-06-30 | -$14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$17.00K 10-Q · filed 2024-08-06 | -$6.70M derived: sum of 3 quarters · filed 2026-02-17 | -$159.00K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2024-03-31 | -$3.00K 10-Q · filed 2024-05-07 | -$6.69M derived: sum of 2 quarters · filed 2026-02-17 | -$145.00K derived: sum of 3 quarters · filed 2026-02-17 | -$453.00K derived: sum of 4 quarters · filed 2026-02-17 | |
| 2023-12-31 | -$6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | -$142.00K derived: sum of 2 quarters · filed 2026-02-17 | -$450.00K derived: sum of 3 quarters · filed 2026-02-17 | -$193.00K 10-K · filed 2026-02-17 | |
| 2023-09-30 | $6.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $6.24M derived: sum of 2 quarters · filed 2024-11-04 | $6.49M 10-Q · filed 2024-11-04 | $3.25M derived: sum of 4 quarters · filed 2025-02-18 | |
| 2023-06-30 | -$308.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$51.00K 10-Q · filed 2024-08-06 | -$3.29M derived: sum of 3 quarters · filed 2025-02-18 | -$128.00K derived: sum of 4 quarters · filed 2025-02-18 | |
| 2023-03-31 | $257.00K 10-Q · filed 2024-05-07 | -$2.98M derived: sum of 2 quarters · filed 2025-02-18 | $180.00K derived: sum of 3 quarters · filed 2025-02-18 | -$229.00K derived: sum of 4 quarters · filed 2025-02-18 | |
| 2022-12-31 | -$3.24M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$77.00K derived: sum of 2 quarters · filed 2025-02-18 | -$486.00K derived: sum of 3 quarters · filed 2025-02-18 | -$892.00K 10-K · filed 2025-02-18 | |
| 2022-09-30 | $3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.75M derived: sum of 2 quarters · filed 2023-11-07 | $2.35M 10-Q · filed 2023-11-07 | $2.43M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-06-30 | -$409.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$815.00K 10-Q · filed 2023-08-10 | -$730.00K derived: sum of 3 quarters · filed 2024-02-20 | -$1.04M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2022-03-31 | -$406.00K 10-Q · filed 2023-05-09 | -$321.00K derived: sum of 2 quarters · filed 2024-02-20 | -$628.00K derived: sum of 3 quarters · filed 2024-02-20 | -$2.23M derived: sum of 4 quarters · filed 2024-02-20 | |
| 2021-12-31 | $85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | -$222.00K derived: sum of 2 quarters · filed 2024-02-20 | -$1.82M derived: sum of 3 quarters · filed 2024-02-20 | -$774.00K 10-K · filed 2024-02-20 | |
| 2021-09-30 | -$307.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$1.90M derived: sum of 2 quarters · filed 2022-11-08 | -$859.00K 10-Q · filed 2022-11-08 | ||
| 2021-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$552.00K 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $1.04M 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | $1.88M 10-K · filed 2023-03-07 | ||||
| 2019-12-31 | $0.00 10-K · filed 2022-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |